AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Ramsay Health Care Shares Surge 4.6% on Tuesday. Here's Why.
February 11, 2025 11:23 AM AEDT| By Team Kalkine MediaHighlights,Ramsay Health Care shares jumped,4.6% to AU$35.81,, their highest level since December 2023.,The company forecasts,1H25 underlying NPAT of AU$150M–AU$160M,, exceeding analyst expectations.,Ramsay flagged a,AU$305M impairment,for its UK seg...
CSL Shares Edge Higher on Half-Year Results, Targets 10-13% NPATA Growth
February 11, 2025 11:19 AM AEDT| By Team Kalkine MediaHighlights,CSL shares rose 0.5% to AU$271.68 following the release of its half-year FY25 results.,Revenue grew 5% to US$8.48 billion, while net profit after tax (NPAT) increased 7% in constant currency.,Despite missing consensus estimates, CSL reaffi...
Citi Raises Ansell Price Target Amid Earnings Update and Upgraded Guidance
February 11, 2025 11:12 AM AEDT| By Team Kalkine MediaHighlights,Citi increased its price target for Ansell to AU$38, up from AU$32.50.,Ansell’s 1H25 adjusted EPS of 55.7 US cents beat consensus estimates by 9%.,The company upgraded its FY25 EPS forecast and expects further earnings growth from acquisit...
CSL’s Plasma Strength, Alcidion’s UK Growth, and Cann Group’s Expansion: Key Market Insights
February 11, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,CSL’s (ASX:CSL) Plasma Business Drives Growth,– Strong demand for immunoglobulin products offsets flu vaccine challenges, boosting net profit by 7% to US$1.9 billion.,Alcidion (ASX:ALC) Expands in UK Healthcare,– Secures a $5.5 million con...
CSL (ASX:CSL) Delivers Resilient HY25 Results Amid Market Challenges
February 11, 2025 10:52 AM AEDT| By Team Kalkine MediaHighlights,Revenue Growth:,5% increase in HY25, reaching,$8.48 billion,at,constant currency (CC).,Profit Expansion:,Underlying net profit rose 5% at CC to $2.11 billion.,Dividend Boost:,Interim dividend jumped 16% to A$2.08 per share.,CSL (ASX:CSL),...
CSL shares increased by 6% due to strong demand for its CSL Behring division.
February 11, 2025 10:30 AM AEDT| By Team Kalkine MediaCSL shares increased by 6% due to strong demand for its CSL Behring division.
Stakeholder Dynamics at Ramsay Health Care (ASX:RHC)
February 11, 2025 09:31 AM AEDT| By Team Kalkine MediaHighlights,Institutions hold a 41% stake in Ramsay Health Care (RHC).,The top seven shareholders control over half of the company.,General public maintains significant influence in company decisions.,Ramsay Health Care Limited (ASX:RHC) has a diverse...
Mayne Pharma (ASX:MYX) Shares Surge on Strong Forecast for 275% Revenue Growth
February 10, 2025 01:41 PM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma (,ASX:MYX,) shares jump 20.5% on positive forecast,Forecasted earnings before interest, tax, depreciation, and amortization (EBITDA) to increase by up to 300%,Revenue set to exceed $210 million, showing strong year-over-year g...
Ansell Shares Surge to Three-Year High on Strong Earnings Outlook
February 10, 2025 01:29 PM AEDT| By Team Kalkine MediaHighlights,Ansell shares hit a three-year high, jumping 6.7% to AU$37.26.,Company raises FY25 earnings guidance, beating analyst expectations.,First-half FY25 sales reach $1.02 billion, up 12.5% year-over-year.,Shares of,Ansell Ltd (ASX:ANN),soared,6...
Mayne Pharma (ASX: MYX) Forecasts Strong 1H25 Revenue Growth with Robust EBITDA Surge
February 10, 2025 12:59 PM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma expects up to $215 million in revenue for 1H25.,Projected EBITDA increase of,nearly 300%,year-on-year.,Focus on Women’s Health and Dermatology driving growth.,Mayne Pharma (ASX: MYX) is forecasting strong financial performance...
Evaluating Cochlear Limited's Stock Valuation A Comprehensive Analysis
February 09, 2025 03:31 PM AEDT| By Team Kalkine MediaEvaluating Cochlear Limited's Stock Valuation A Comprehensive Analysis
Does Oneview Healthcare's Ownership Makeup Reflect a Broad Investor Base?
February 08, 2025 03:30 PM AEDT| By Team Kalkine MediaHighlights,A majority of the shares are possessed by individual investors.,A select group of major shareholders manages a considerable portion of the distribution.,Recent share acquisitions by company management have been recorded.,Oneview Healthcare...
Neuren Pharmaceuticals (ASX:NEU) Advances FDA Discussions for Phase 3 Clinical Trial
February 07, 2025 11:22 AM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals (,ASX:NEU,) has secured a Type C meeting with the FDA to discuss efficacy endpoints for its Phase 3 trial of NNZ-2591.,NNZ-2591 showed promising results in treating neurodevelopmental disorders, including Phelan-McDe...
ASX Healthcare Stocks: Navigating Global Tariff Pressures and Market Volatility
February 07, 2025 11:00 AM AEDT| By Team Kalkine MediaASX Healthcare Stocks: Navigating Global Tariff Pressures and Market Volatility
Orthocell's Remarkable Performance Navigating Rapid Revenue Growth and Dynamic Stock Gains
February 07, 2025 09:32 AM AEDT| By Team Kalkine MediaOrthocell's Remarkable Performance Navigating Rapid Revenue Growth and Dynamic Stock Gains
Compumedics Limited (ASX:CMP) Unraveling Valuation Discrepancies Amid Robust Revenue Growth
February 07, 2025 09:31 AM AEDT| By Team Kalkine MediaCompumedics Limited (ASX:CMP) Unraveling Valuation Discrepancies Amid Robust Revenue Growth
Is SGH Limited's Valuation Justified by Its Growth Outlook?
February 06, 2025 05:34 PM AEDT| By Team Kalkine MediaHighlights,SGH Limited operates within a dynamic healthcare and property services sector.,The company trades with a price-to-earnings ratio considerably above the market average.,Market expectations point to higher future growth compared to other Aus...
A Look at Neuren Pharmaceuticals Limited (ASX:NEU) and Its Current Valuation
February 06, 2025 03:19 PM AEDT| By Team Kalkine MediaHighlights:,Neuren Pharmaceuticals,(ASX:NEU),operates within the biotechnology sector, focusing on treatments for neurological disorders.,The company's current valuation is based on a financial assessment of expected future cash flows.,A Discounted C...
AdAlta (ASX:1AD) Unveils 'East to West' Strategy, Shifting Focus from AD-214
February 06, 2025 11:38 AM AEDT| By Team Kalkine MediaHighlights:,New Strategic Direction:,AdAlta,(ASX:1AD) has introduced its 'East to West' strategy, aiming to source cellular immunotherapy candidates from Southeast Asia, refine them through,early-stage,testing in Australia, and license them to Wester...
Health Check: When Record Results Fall Short of Investor Expectations
February 06, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,PolyNovo Reports Market Fluctuations:,Despite strong financial results, PolyNovo (ASX:PNV) experienced stock price movements due to revenue and profit figures falling slightly below market expectations.,Cyclopharm Expands in the US:,Cyclo...
Advertise your brand on Kalkine Media